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Abstract
This article summarises the information to be offered to wom-
en about mammography. After a delineation of the aim of
early diagnosis of breast cancer, the difference between
screening mammography and diagnostic mammography is
explained. The need to bring images and reports from the
previous mammogram (and from other recent breast imaging
examinations) is highlighted. Mammography technique and
procedure are described with particular attention to discomfort
and pain experienced by a small number of women who un-
dergo the test. Information is given on the recall during a
screening programme and on the request for further work-up
after a diagnostic mammography. The logic of the
mammography report and of classification systems such as
R1-R5 and BI-RADS is illustrated, and brief but clear infor-
mation is given about the diagnostic performance of the test,
with particular reference to interval cancers, i.e., those cancers
that are missed at screening mammography. Moreover, the
breast cancer risk due to radiation exposure from mammogra-
phy is compared to the reduction in mortality obtained with
the test, and the concept of overdiagnosis is presented with a
reliable estimation of its extent. Information about new mam-
mographic technologies (tomosynthesis and contrast-
enhanced spectral mammography) is also given. Finally, fre-
quently asked questions are answered.
Key Points
• Direct digital mammography should be preferred to film-
screen or phosphor plates.
• Screening (in asymptomatic women) should be distinguished
from diagnosis (in symptomatic women).
• A breast symptom has to be considered even after a negative
mammogram.
• Digital breast tomosynthesis increases cancer detection and
decreases the recall rate.
• Contrast-enhanced spectral mammography can help in can-
cer detection and lesion characterisation.
Keywords Breast cancer .Mammography . Screening .
Digital breast tomosynthesis (DBT) . Contrast-enhanced
spectral mammography (CESM)
Introduction
Malignant tumours (cancers) and benign diseases are very
common in the breast. Aside from clinical history (disorders
in the family, previous breast diseases/surgery, hormone
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therapy, personal well-being and complaints), inspection (ex-
ternal viewing) and palpation, which compose the so-called
clinical breast examination, imaging procedures and especial-
ly mammography are of crucial importance in the detection
and diagnosis of breast cancer and also other breast diseases.
Mammography is a specialised radiography of the breast
using x-rays for generating images of the breast. Its purposes
are first early detection of breast cancer before symptoms
(screening mammography) and second diagnosis in patients
with symptoms such as a palpable lump (diagnostic
mammography, also named clinical mammography).
This article—specifically aimed at summarising the most
important information to be offered to women about mam-
mography—updates a previous article published in 2012 [1]
by the European Society of Breast Imaging (EUSOBI), taking
in consideration the most recent evidence in favour of mam-
mography and of two mammographic technique tools now
available for clinical practice: digital breast tomosynthesis
(or simply tomosynthesis) and contrast-enhanced spectral
mammography (CESM). Here we also took into account the
recent position paper on screening for breast cancer by
EUSOBI and 30 national breast radiology bodies [2], which
should be considered complementary to the current article.
Screening and diagnostic mammography
Mammography is the most important imaging procedure for
breast cancer detection and diagnosis. The general aim is to
enable early treatment of breast cancer, to improve survival
rates and to reduce the need for aggressive treatment such as
mastectomy [3, 4], also in the current era of modern therapies
[5, 6]. It can be performed in a screening setting or a diagnos-
tic setting. In both settings, whenever possible, preference
should be given to full-field digital mammography (not
phosphor-plate computer radiography) instead of film-
screen mammography, taking in consideration a number of
relevant advantages for the women who get a mammogram
and for the general population, including lower x-ray dose,
higher image quality, possibility of post-processing, digital
archiving, image transmission and no chemical pollution [2,
7].
Screening mammography Screening is performed periodi-
cally in order to find small cancers before they are detected
through self-palpation or clinical breast examination.
Mammography is performed every 1, 2 or 3 years from the
age of 40–50 years until around 70–75, depending on
national/regional screening programmes. European guidelines
suggest the 2-year interval for the general female population
from 50 to 70 years of age [8]. Relevant differences in screen-
ing programmes across European countries, including ways of
reporting, are due to differences in culture, technical
circumstances, biopsy options, financial restrictions and breast
cancer prevalence. Women with a high frequency of breast
cancer in their family should start even earlier with periodic
imaging, possibly with protocols including contrast-enhanced
magnetic resonance imaging (MRI) [9, 10], after consulting
specialised centres, since mammograms in those conditions
may have a very limited diagnostic power.
Screening mammography is a standardised procedure com-
posed of four views (also named projections), two for each
breast: the cranio-caudal projection and the medio-lateral
oblique projection. In some countries, clinical breast exami-
nation is a part of the procedure, even though its added value
in the screening setting, when mammography is performed, is
negligible [4]. Screening mammography can be performed by
a radiographer alone; the resulting images are usually read by
two radiologists, independently, in separate sessions. If the
examination is judged to not reveal any abnormality suspi-
cious for malignancy, the woman receives a letter communi-
cating this result. If something suspicious is found, the woman
is recalled for a tailored further assessment that can be variably
composed of add i t iona l mammograph ic v iews ,
tomosynthesis, ultrasound, MRI, CESM or needle biopsy.
When this assessment is concluded, a formal written report
will be prepared by the radiologist and given to the woman
during a dedicated interview for complete information.
Diagnostic mammography This is performed in patients pre-
senting with clinical symptoms such as a palpable lump, nip-
ple discharge, skin thickening and/or nipple retraction in order
to diagnose or exclude breast cancer. Diagnostic mammogra-
phy is usually performed by a radiographer and images are
immediately available for the radiologist to assess. Before or
after the bilateral acquisition of the two standard projections
already mentioned for screening mammography, a full clinical
breast examination is performed by the radiologist. This is
particularly important when results of a full clinical breast
examination recently performed by another doctor are not
available. According to the radiologist’s preference, palpable
lumps, scars from previous surgeries or other abnormalities
can be highlighted by positioning a marker on the skin. If
necessary, additional views are acquired after the standard
procedure, and further assessment can be performed as above
described for women with suspicious findings at screening
mammography. A formal written report is always prepared
by the radiologist with conclusions, including recommended
further steps.
Note A. If you notice relevant symptoms in your breast,
ask immediately for an appointment with your primary
care physician in order to decide if you need a diagnostic
mammography. Alternatively, you may also directly ask
your breast radiologist for a prompt evaluation. This
advice is also valid even if you recently had a screening
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mammography that did not reveal suspicious findings.
However, if you have symptoms and you are getting a
screening mammography, inform the radiographer
about them! The radiologists reading your images will
be informed about this and will decide whether you
should be recalled based on these symptoms. In any
case, if your symptoms do not disappear, you should
consult your radiologist even if your mammography
has been judged negative.
Scheduling/precautions
The best time for a less painful mammography to be carried
out is from day 7 to day 12 after the beginning of the woman’s
last menstruation. No particular scheduling is required after
menopause, implying that for the majority of mammograms
performed in the context of population-based screening
programmes scheduling has no limitations. If the woman is
pregnant, ultrasound is preferred as a first option.
Note B. You should bring images and reports from the
previous mammograms (and from other recent breast
imaging examinations) and give these to the radiogra-
pher or the radiologist before the procedure. This can be
crucial for image interpretation due to the fact that some
cancers are diagnosed only on the basis of changes that
have occurred after a previous examination.
Technique/procedure
Mammography is performed using a dedicated x-ray unit. A par-
ticular radiographic technique is used requiring the compression of
the breast for 5–10 s in order to deliver a low radiation dose and to
obtain high-quality images. As already mentioned, it is standard
practice to take two views per breast and additional views in
special cases. The procedure is performedwith thewoman’s upper
bodyundressed.All foreign objects (such as bras, necklaces, pierc-
ings, etc.)must be removed before the procedure. Thewomanwill
stand in an upright position in front of the machine. For each
projection of each breast, the radiographer will place the breast
on the plate andwill carefully apply a progressive compression for
5–10 s. During breast squeezing, women may feel some pain or
discomfort [11]. It is important not to move during this short time.
Immediately after acquiring the mammogram, the breast will be
released from compression. The entire bilateral standard proce-
dure, including preparation, takes approximately 5–10 min.
Note C. To reduce pain or discomfort due to breast com-
pression and to get the best mammograms, you should
relax during the procedure; in particular, the pectoral
muscles should be relaxed. Follow the radiographer’s
instructions exactly and bear in mind that heavier com-
pression means a lower x-ray dose, higher image quality
and easier diagnosis. If you previously experienced a
painful mammography in the premenstrual phase, try
to arrange the next one from day 7 to day 12 of your
cycle.
After the procedure
When the procedure is over, the woman returns to the waiting
room. In the case of screening mammography, she is usually
only informed whether or not the acquired images are techni-
cally adequate. If no views need to be repeated, she may leave.
She will receive a letter communicating that the mammogram
is negative or she will be informed, usually through a phone
call, that further assessment is needed (recall). The first event
is far more probable (over 90–95 % of cases). In some coun-
tries, only positive screening examinations (recalls) are com-
municated. In the case of diagnostic mammography, after
checking the technical adequacy, the radiologist immediately
informs the patient either that the examination is completely
negative or that further assessment is needed, as already
mentioned.
Note D. If you are recalled after a screening mammo-
gram or you are asked to have an ultrasound after a
diagnostic mammography, this does not mean that you
have a cancer. The most probable result of this second
examination, especially in the screening setting, is a
higher level of certainty in stating that you do not have
cancer! Less than 10 % of women recalled at screening
are finally diagnosed with cancer. However, if a cancer
were present, you would rightly like it to be diagnosed
as early as possible.
Mammography report and classification systems
Diagnostic mammography and also diagnostic assessment of
recalled women after mammography screening should be for-
mally carried out by a certified breast radiologist. A detailed
report should include a description of the clinical context, if
relevant, as well as image findings, including breast density
and structure according to different classification systems, in-
terpretation of the described findings and a final conclusion
with recommendations. In many European countries,
standardised classification systems for the conclusions of
mammography reports are used. A European system uses
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the five-level scale from R1 to R5, where R stands for radiog-
raphy. R1 means no abnormalities, R2 benign findings, R3
equivocal findings, R4 suspected cancer and R5 strongly
suspected cancer. A system developed in the USA, the
Breast Imaging Reporting and Data System (BI-RADS)
[12], also used in many European countries, includes a similar
scale, from BI-RADS 1 to BI-RADS 5. The main difference is
for BI-RADS 3, which implies a very low probability of can-
cer (less than 2 %), allowing the possibility of waiting for a
short interval (usually 3–6 months) before a repeat mammo-
gram. Conversely, the R3 category indicates a probability of
cancer that is higher than that of BI-RADS 3. Moreover, the
BI-RADS score system also includes BIRADS 0 (examina-
tion insufficient for a diagnostic conclusion; further work-up
needed) and BI-RADS 6 (evaluation of an already diagnosed
cancer).
Note E. In practice, if you have an R4–R5 or a BI-
RADS 4–5 finding, needle biopsy is recommended. In
case of R3 or BI-RADS 3, meet your radiologist and ask
for a detailed explanation of this result, of the risks and
probabilities associated with different options.
Diagnostic performance of mammography
No diagnostic test is perfect. This rule also applies to mammog-
raphy. When thinking about screening, women should be aware
that about 28 % of cancers can be missed [13, 14], especially in
pre-menopausal women and in those with dense breasts. This
means that if we consider 1000women getting a screeningmam-
mogram, if 8–10 cancers are present, 2 or 3 can be missed,
mostly because they are difficult to distinguish from normal
breast tissue. Still, mammography is the best proven method
for screening average-risk women.
Note F. Do not underestimate the importance of breast
symptoms (especially a new palpable lump, skin/nipple
retraction or nipple discharge), regardless of the timing
of your last negative mammogram. Go to your radiolo-
gist and ask for a visit. Tell her/him your symptoms and
she/he will decide the best course of action for you.
Conversely, not all suspicious findings visualised on a
mammogram are cancers: depending on the level of
suspicion, cancer is confirmed in a highly variable pro-
portion of cases. When the suspicion is confirmed after
further assessment, image-guided needle biopsy is man-
datory before planning any treatment.
Note G. A suspicious mammographic finding is not a
confirmed cancer. However, do not postpone further as-
sessment and, if necessary, needle biopsy.
Radiation exposure from mammography
The radiation exposure for a mammogram is low. A study [15]
reported that undergoing repeated mammograms over a time
period of 34 years (annual from age 40 to 55 years and biennial
from 56 to 74 years) entails a risk of radiation-induced breast
cancer equal to 1 in every 1000 women screened. The risk of
breast cancer in the female population of western countries is
equal to at least one in every ten women. The first risk is 100
times smaller than the second, while the reduction in breast
cancer mortality thanks to early detection with screening mam-
mography is about 40 % [4]. Another study [16], applying a
mortality reduction rate of 43 % as an effect of screening mam-
mography, also considering the Bminimal^ risk of radiation-
induced cancers, found that biennial screening mammography
performed in 100,000 women age 50–69 saves 350 lives.
However, for the 40–49 age range, the problem of radiation
effects depends on the estimated magnitude of radiation-
induced BCs in this younger age interval and must be more
carefully considered. Importantly, even in the rare case of
radiation-induced breast cancer, in a screening setting most of
these will be detected early and treated. In symptomatic women,
when a mammogram is necessary, the advantages always
outweight the disadvanges, independently from the patient age.
Overdiagnosis
Not all the breast cancers diagnosed with screening are
aggressive and fatal cancers. In the absence of screening
mammography, some breast cancers—estimated to be
about 6.5 %, with a range from 1 % to 10 % [4]—
would have remained totally free of symptoms because
of the very slow growth of these types of lesions, which
do not tend to advance outside the breast [17].
However, these cancers cannot be distinguished from
those that, if left undiagnosed and untreated, would be
fatal. Thus, if we want to reduce breast cancer mortality,
we must accept a rate of overdiagnosed cancers with the
consequence of a rate of unnecessary treatment, mainly
including surgery and radiation therapy. An effective
representation of the balance between early diagnosis
and overd iagnos i s has been prov ided by the
Euroscreen working group [18]: for every 1,000 women
screened from 50 to 69 years of age, 7–9 breast cancer
deaths are avoided, 4 breast cancers are overdiagnosed,
170 women have at least one recall followed by nonin-
vasive assessment with a negative result, and 30 women
have at least one recall followed by invasive procedures
with a negative result. In practice, the probability of an
individual woman’s life being saved is double that of
being overdiagnosed.
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New mammographic techniques: tomosynthesis
and contrast-enhanced spectral mammography
Two further developments of digital mammography were re-
cently introduced into clinical practice: tomosynthesis and
CESM. Both techniques are intended to overcome some lim-
itations of mammography by reducing summation effects
(tomosynthesis) or by increasing contrast differences
(CESM), especially, but not only, in women with dense breast
tissue. In these women, tumours can be masked because of
overlying breast tissue and lack of contrast to the adjacent
normal breast tissue is common. So far, these techniques have
mainly been proposed as an adjunct to mammography in
women with inconclusive findings in their initial mammo-
grams, with interesting results. Tomosynthesis has also been
positively evaluated as a screening tool.
Tomosynthesis This is obtained with the same mammograph-
ic unit that acquires either the usual digital mammograms or
tomosynthesis studies. The same cranio-caudal and medio-
lateral oblique views are acquired for both examinations and
the patient preparation and positioning are alike. The most
important difference is the use of a moving x-ray source in
tomosynthesis. During a tomosynthesis examination, the x-
ray source moves following an arc over the breast and ac-
quires several projections. At the end, numerous images per
view are obtained, each of them showing a slice of the breast
[19–21]. Tomosynthesis can be acquired as an additional im-
aging to the usual mammograms or it can be acquired alone.
The latter protocol is possible because images very similar to
the usual mammograms can be reconstructed from the
tomosynthesis data set: these so-called synthetic
mammograms can avoid the need for acquiring the original
usual mammograms [20, 22]. According to the device used,
radiation exposure is equal to slightly higher, as compared to
mammography, but it is still within the limits recommended
by international radiation safety guidelines [23]. Results of
different studies comparing mammography alone with mam-
mography with tomosynthesis demonstrated that
tomosynthesis is able to significantly increase cancer detec-
tion up to 30–40 % [21].
Tomosynthesis is already used as a screening modality in
the USA. In Europe, only a few centres perform
tomosynthesis in organised screening programmes, mostly
in the context of research programmes approved by Ethical
Committees. The results of these studies are promising. Three
prospective studies showed that DBT used as an adjunct
[24–26] or alternative [27] to the usual digital mammograms
allows for a superior diagnostic performance when compared
to mammography alone. Overall, tomosynthesis provides an
increase in detection rate from 0.5 to 2.7 per 1000 screened
women as well as a reduction in recall rate from 0.8 to 3.6 per
100 screened women [28]. All these aspects will probably
confer to tomosynthesis the status of future routine
mammography also in the screening setting.
However, before introducing tomosynthesis in breast can-
cer screening outside ethically approved trials, there should be
evidence for a statistically significant and clinically relevant
reduction in the interval cancer rate. This cautiousness is due
to the need to avoid an increase in overdiagnosis and costs.
First results for a reduction from 0.7 to 0.5 interval cancers per
100 screened women were recently reported from a large
study in the US [29], but further evidence is needed.
Note H. During a breast examination performed outside
the screening setting, it is the choice of the radiologist
whether to perform only mammography, to associate
tomosynthesis and/or ultrasound, or also to perform
tomosynthesis without standard mammography and to
obtain reconstructed synthetic mammograms. This de-
cision is based on various issues: the characteristics of
the breast, the availability of previous examinations, the
availability of technology and also the radiologist’s pref-
erence in relation to the specific case.
Note I. If you are invited to attend a screening pro-
gramme where tomosynthesis is proposed in the context
of a study or as routine practice, consider that the poten-
tial advantages of tomosynthesis in terms of increased
cancer detection and reduced recall rate should over-
come the modest increase in radiation dose.
Contrast-enhanced spectral mammography As with
contrast-enhanced MRI, the basis of contrast-enhanced mam-
mography is the fact that, during the development and growth
of a tumour, it develops its own new blood vessels, which can
be a bit leaky, allowing an intravenously injected contrast
agent to enrich the tumour. This enhances the contrast of the
tumour compared to the surrounding tissue. To be able to
show this tumour contrast uptake in a mammographic image,
you have to acquire two exposures of the breast within the
time of one compression, each of them with a different x-ray
energy composition, a technical possibility available for some
newmammographic units. This results in a low-energy image,
identical with a normal mammogram, and a high-energy im-
age containing information about contrast agent distribution in
the breast; the use of different energies is the reason for the
denomination spectral mammography. Depending on the
breast composition and thickness, this causes an extra radia-
tion dose of approximately 20 %, but both images together
still imply an x-ray dose below the recommended dose for
mammography [30–33].
Before the acquisition of the two images started, an iodin-
ated contrast agent has to be intravenously injected. This is
usually done while the patient is seated near the mammo-
graphic unit. Two minutes after the start of the injection, the
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patient is guided to the mammography system and po-
sitioned similarly as with a normal mammography ex-
amination. Within roughly 5 min, the usual cranio-
caudal and medio-lateral oblique views of both breasts
are taken bilaterally, each of them composed by a low-
energy and a high-energy image. The combination of
the two images by a dedicated software allows for
obtaining a new image where the presence of contrast
uptake is easily recognised.
The diagnostic performance of CESM has been re-
cently summarised by a systematic review and meta-
analysis [34], i.e. a combination of the results of previ-
ously published CESM studies. The authors identified
eight studies (4 prospective and 4 retrospective) for a
total of 920 patients with 994 lesions. The ability to
detect existing cancers (sensitivity), estimated from all
studies, resulted to be about 98 % while the ability to
recognise the normal condition in the absence of any
false-positive finding (specificity), estimated from six
studies reporting raw data, was about 58 %. The major-
ity of included studies were judged to have examined
very selected populations. Mean cancer size, reported
only in three studies, was 21.2 mm. The authors con-
cluded that high-quality studies are required to assess
the CESM accuracy. In practice, CESM still deserves
evaluation and the results of this meta-analysis cannot
be considered as conclusive. Interestingly, two recent
studies confirmed a high sensitivity of CESM (94–
95 %) with higher values of specificity: 81 % in the
symptomatic setting [35] and 74 % in the post-screening
assessment [36].
On the basis of still preliminary results, CESM can be consid-
ered as an alternative to contrast-enhanced MRI in the case of
contraindications toMRI (including the presence ofMRI-unsafe
devices in the patient’s body, claustrophobia and obesity
preventing the patient from entering the magnet) or to
gadolinium-based contrast injection as well as local conditions
of difficult MRI availability [9, 10] due to interesting results
obtaining by comparing CESM and MRI in the same patients
[37, 38].
Note J. It is important to note that iodinated contrast agents
are frequentlyusedinclinicalpractice,mostly intravenous-
ly injected for contrast-enhanced computed tomography.
There are contraindications (history of allergic reactions,
renal failure) and possible side effects that require discus-
sionwith the patient and the signature of an informedwrit-
tenconsent.Thus, the injectionof iodinatedcontrast agents
for mammography requires the same precautions used for
othercontrast-enhancedx-ray-basedexamination[39,40].
Before theexamination, theradiologistwillclarify therisks
and benefits associated with the intravenous injection of
iodinated contrast agents.
Frequently asked questions (FAQs)
How painful is breast compression for mammography?
Mammography is tolerated well by the vast majority of
women. In particular, it is painless for about 40–50 %
of women, a little painful for 40 %, rather painful for
12 % and very painful only for 4 %. Pain disappears
immediately after the procedure for 76 % of the women,
while it lasts several minutes for 13 %, several hours
for 7 % and more than 1 day for 4 % [11]. However,
the advantages of compression are clear, and unneces-
sary pain may sometimes be avoided by suitable sched-
uling (see Note C). The radiographer will guide you
through all the steps of the examination and will take
care of minimising the discomfort during breast
compression.
When should the first mammogram be done? What are
the time intervals for further examinations?
Different recommendations are issued by different radio-
logical and cancer societies as well by health authorities
and governmental bodies. There is a general agreement
on the usefulness of screening mammography from 50
to 70 years of age, with a time interval depending on
several factors described above. Extension from about
40–45 to about 75 is now adopted by several screening
programmes. When starting at 40, a 1-year interval can
be recommended up to 45–50, considering the probable
higher density and the possible faster growth of the
tumour. After 50, the optimal interval may be decided
based on personal history and breast density. If you
have symptoms, mammography may be necessary for
you at any age. If you are a woman with an increased
risk for breast cancer (gene mutation carrier, multiple
breast/ovarian cancer in the family), screening should
start before age 40, according to your personal calculat-
ed risk level, access to special screening programmes,
and other factors.
Note K. If you are invited to attend an organised screen-
ing programme, follow the programme’s planned inter-
val. If you have any doubts about this time interval, or
the usefulness of ultrasound as a supplemental screening
method, consult your radiologist. If there are a high
number of incidences of breast cancer in your family,
especially at a young age and before menopause, you
may need to have a screening with MRI [9, 10]: consult
your radiologist and/or a specialised centre (e.g. a family
cancer clinic). Information on indications to MRI are
available in a EUSOBI dedicated paper [10].
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What about screening mammography for women
over 75?
The continuous increase in life expectancy prevents defining a
clear cut upper age limit for screening mammography. A gen-
eral suggestion is to continue screening with mammography
for elderly women as long as their health is not significantly
compromised by illness that drastically reduces life expectan-
cy [41, 42]. Discuss this decision with your radiologist.
Can women with breast implants or breast reconstruction
undergo mammography?
Yes, in the majority of cases they can. Special views with back
placement of the implant are commonly needed, as well as
specific technical expertise by the radiographer. Exceptions
where mammography cannot be performed are breast recon-
s t ruc t ions af ter comple te g land t issue removal .
Mammography limitations due to the presence of implants
can be counteracted by an accurate clinical breast examination
and breast ultrasound.
Note L. Always tell the radiologist and/or the radiogra-
pher if you have breast implants.
Is x-ray radiation from mammography dangerous?
The x-ray radiation associated with a mammogram is low. See
in this article the section BRadiation exposure from
mammography^ for a comparison between the risk of
radiation-induced breast cancer and the reduction of breast
cancer mortality due to mammography.
What is the role of new technologies like tomosynthesis
and CESM?
The role of these new technologies is to help in the detection
and diagnosis of breast cancers. Tomosynthesis is commonly
accepted as an effective tool for evaluation of symptomatic
patients and suspicious findings at screening mammography.
Large studies in the screening setting showed that
tomosynthesis allows the identification of more cancers than
mammography and potentially reduces the number of women
recalled for benign findings. So far, CESM has been evaluated
in a limited number of small studies. It provides useful infor-
mation of suspicious lesions, increasing the visibility of ma-
lignant lesions, in particular in women with dense breasts, and
can be an alternative to contrast-enhanced MRI, especially in
the case of contraindications to MRI or to gadolinium-based
contrast injection as well as of difficult MRI availability.
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